- Home
- QUMS vs ARMP Comparison
QUMS vs ARMP Comparison
Compare QUMS & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUMS
- ARMP
- Stock Information
- Founded
- QUMS 2024
- ARMP N/A
- Country
- QUMS United States
- ARMP United States
- Employees
- QUMS N/A
- ARMP N/A
- Industry
- QUMS
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QUMS
- ARMP Health Care
- Exchange
- QUMS Nasdaq
- ARMP Nasdaq
- Market Cap
- QUMS 113.7M
- ARMP 125.7M
- IPO Year
- QUMS 2025
- ARMP N/A
- Fundamental
- Price
- QUMS N/A
- ARMP $6.48
- Analyst Decision
- QUMS
- ARMP Strong Buy
- Analyst Count
- QUMS 0
- ARMP 1
- Target Price
- QUMS N/A
- ARMP $9.00
- AVG Volume (30 Days)
- QUMS 21.7K
- ARMP 796.6K
- Earning Date
- QUMS 01-01-0001
- ARMP 11-12-2025
- Dividend Yield
- QUMS N/A
- ARMP N/A
- EPS Growth
- QUMS N/A
- ARMP N/A
- EPS
- QUMS N/A
- ARMP N/A
- Revenue
- QUMS N/A
- ARMP $5,054,000.00
- Revenue This Year
- QUMS N/A
- ARMP $8.43
- Revenue Next Year
- QUMS N/A
- ARMP N/A
- P/E Ratio
- QUMS N/A
- ARMP N/A
- Revenue Growth
- QUMS N/A
- ARMP N/A
- 52 Week Low
- QUMS $9.92
- ARMP $0.90
- 52 Week High
- QUMS $10.23
- ARMP $16.34
- Technical
- Relative Strength Index (RSI)
- QUMS N/A
- ARMP 60.20
- Support Level
- QUMS N/A
- ARMP $4.65
- Resistance Level
- QUMS N/A
- ARMP $7.30
- Average True Range (ATR)
- QUMS 0.00
- ARMP 0.72
- MACD
- QUMS 0.00
- ARMP 0.06
- Stochastic Oscillator
- QUMS 0.00
- ARMP 65.66
About QUMS Quantumsphere Acquisition Corp. Ordinary Shares
Quantumsphere Acquisition Corp is a newly organized blank check company.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.